The PIM family of oncoproteins: Small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets

Kumar Saurabh, Michael T. Scherzer, Parag P. Shah, Alice S. Mims, William W. Lockwood, Andrew S. Kraft, Levi J. Beverly

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

PIM kinases are a family of serine/threonine kinases involved in cell survival and proliferation. There is significant structural similarity between the three PIM kinases (PIM1, PIM2 and PIM3) and few amino acid differences. Although, several studies have specifically monitored the role of PIM1 in tumorigenesis, much less is known about PIM2 and PIM3. Therefore, in this study we have used in vitro cell culture models and in vivo bone marrow infection/transplantation to assess the comparative signaling and oncogenic potential of each of the three PIM kinases. All three PIM kinases were able to protect FL5.12 cells from IL-3 withdrawal induced death. Interestingly, the downstream signaling cascades were indistinguishable between the three kinases. Transplantation of murine bone marrow co-expressing MYC and PIM1, PIM2 or PIM3 caused rapid and uniformly lethal myeloid leukemia. De-induction of MYC 18 days following transplantation significantly increased the survival of mice, even with continual expression of PIM kinases. Alternatively, mice treated at the pre-leukemic stage with a PIM kinase inhibitor increased the lifespan of the mice, even with continual expression of the MYC transgene. These data demonstrate the role of PIM kinases in driving myeloid leukemia, and as candidate molecules for therapy against human malignancies.

Original languageEnglish (US)
Pages (from-to)8503-8514
Number of pages12
JournalOncotarget
Volume5
Issue number18
DOIs
StatePublished - Jan 1 2014

    Fingerprint

Keywords

  • Leukemia
  • MYC
  • PIM-1
  • PIM-2
  • PIM-3

ASJC Scopus subject areas

  • Oncology

Cite this